Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Patent metadata

Field	Value
Publication number	US-12019080-B2
Application number	US-202117409168-A
Country	US
Kind code	B2
Filing date	Aug 23, 2021
Priority date	Jan 17, 2013
Publication date	Jun 25, 2024
Grant date	Jun 25, 2024

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

First claim

We claim:

1. A method of treating a subject at risk of acute kidney injury, the method comprising:
combining
i) a measured value for one or more of an amount of Tissue Inhibitor of Metalloproteinase 2 (TIMP2) and an amount of Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in a body fluid sample, and
ii) a measured value for one or more of a serum creatinine concentration and urine output,

into a single composite value;
correlating the single composite value to a risk of acute kidney injury in the subject, wherein the single composite value is above a threshold indicative of a relatively increased risk of acute kidney injury; and
treating the subject based on the subject's relatively increased risk of acute kidney injury with a compatible treatment, wherein the compatible treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying procedures that are known to be damaging to the kidney, and modifying diuretic administration.

2. The method of claim 1 , wherein the single composite value is calculated as a urinary TIMP2 concentration x a urinary IGFBP7 concentration x the serum creatinine concentration; a urinary TIMP2 concentration x a urinary IGFBP7 concentration/the urine output; a urinary TIMP2 concentration x a urinary IGFBP7 concentration x the serum creatinine concentration/the urine output; a urinary TIMP2 concentration x a serum creatinine concentration; a urinary TIMP2 concentration/the urine output; a urinary TIMP2 concentration x the serum creatinine concentration/the urine output; a urinary IGFBP7 concentration x the serum creatinine concentration; a urinary IGFBP7 concentration/the urine output; or a urinary IGFBP7 concentration x the serum creatinine concentration/the urine output.

3. A method of treating a subject at risk of progressing to future stage I (Injury) or stage F (Failure) acute kidney injury under the RIFLE (Risk, Injury, Failure, Loss, End stage renal disease) classification system, the method comprising:
performing a decision tree analysis having the following steps:

(i) determining whether a single composite value that combines an amount of Insulin-like growth factor-binding protein 7 (IGFBP7) and an amount of Metalloproteinase inhibitor 2 (TIMP2) measured in a body fluid sample from the subject is above a predetermined threshold selected from a population study of individuals known to be at RIFLE stage R, the threshold separating the population into a first subpopulation above the threshold which is at an increased predisposition for progressing to future RIFLE stage I or F acute kidney injury relative to a second subpopulation not above the threshold, and
(ii) determining whether either a) a serum creatinine concentration is greater than or equal to 0.3 mg/dL or increased to greater than or equal to 150% (1.5-fold) of a baseline serum creatinine concentration for the subject, or b) a weight-adjusted urine output value is less than 0.5 mL/kg per hour for more than 6 hours; and
correlating the result of the decision tree analysis to the subject's renal status, wherein (i) and (ii) are determined to both be true for the subject, by assigning to the subject in which (i) and (ii) are true an increased likelihood of progressing to future RIFLE stage I or stage F, relative to an individual for which (i) and (ii) are not both true; and
treating the subject based on the subject's assignment of an increased likelihood of progressing to future RIFLE stage I or stage F with a compatible treatment, wherein the compatible treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying procedures that are known to be damaging to the kidney, and modifying diuretic administration.

4. The method of claim 3 , wherein the risk of progressing to future stage I or stage F is a risk of progressing to future stage I or F within 48 hours of the time the sample was obtained.

5. The method of claim 3 , wherein the risk of progressing to future stage I or stage F is a risk of progressing to future stage I or F within 24 hours of the time the sample was obtained.

6. A method of treating a subject for stage I (Injury) or stage F (Failure) acute kidney injury under the RIFLE (Risk, Injury, Failure, Loss, End stage renal disease) classification system, the method comprising:
correlating a single composite value that combines one or more of a serum creatinine concentration and urine output, an amount of Insulin-like growth factor-binding protein 7 (IGFBP7) and an amount of Metalloproteinase inhibitor 2 (TIMP2) measured in a body fluid sample from the subject to a relatively increased risk of RIFLE stage I or stage F acute kidney injury by determining that the single composite value is above a predetermined threshold selected from a population study of individuals known to have progressed to RIFLE stage R, the threshold separating the population into a first subpopulation above the threshold which is at an increased predisposition for RIFLE stage I or F acute kidney injury relative to a second subpopulation not above the threshold; and
treating the subject based on the subject's assignment of an increased likelihood of RIFLE stage I or stage F acute kidney injury with a compatible treatment, wherein the compatible treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying procedures that are known to be damaging to the kidney, and modifying diuretic administration.

7. The method of claim 6 , wherein the relatively increased risk of RIFLE stage I or stage F acute kidney injury is a risk of progressing to future RIFLE stage I or stage F acute kidney injury.

8. The method of claim 6 , wherein the relatively increased risk of RIFLE stage I or stage F acute kidney injury is a risk of current RIFLE stage I or stage F acute kidney injury.

9. The method of claim 7 , wherein correlating the single composite value to the relatively increased risk of future RIFLE stage I or stage F acute kidney injury further comprises determining that a serum creatinine concentration is above a predetermined serum creatinine threshold selected from a population study of individuals known to have progressed to RIFLE stage R, the serum creatinine threshold separating the population into a first subpopulation above the threshold which is at an increased predisposition for RIFLE stage I or F acute kidney injury relative to a second subpopulation not above the threshold.

10. The method of claim 7 , wherein correlating the single composite value to the relatively increased risk of future RIFLE stage I or stage F acute kidney injury further comprises determining that a serum creatinine concentration is greater than or equal to 0.3 mg/dL or increased to greater than or equal to 150% (1.5-fold) of a baseline serum creatinine concentration for the subject.

11. The method of claim 7 , wherein correlating the single composite value to the relatively increased risk of future RIFLE stage I or stage F acute kidney injury further comprises determining that a urine output is above a predetermined urine output threshold selected from a population study of individuals known to have progressed to RIFLE stage R, the urine output threshold separating the population into a first subpopulation above the threshold which is at an increased predisposition for RIFLE stage I or F acute kidney injury relative to a second subpopulation not above the threshold.

12. The method of claim 7 , wherein correlating the single comp

Assignees

• Astute Medical Inc

Inventors

• Anderberg Joseph
• Gray Jeff
• Mcpherson Paul
• Nakamura Kevin
• Kampf James Patrick

Classifications

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/65

  Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2 · CPC title

• G16B40/20

  Supervised data analysis · CPC title

• Y02A90/10

  Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation · CPC title